2 results
Approved WMOPending
The primary objective is to compare the percentage of patients reaching an effective FBT dose with a starting dose of 100 mcg to those with a starting dose of 200 mcg. Secondary objectives are to evaluate the safety and tolerability and the…
Approved WMORecruiting
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…